In retrospective analyses renal transplant recipients who received either sirolimus or everolimus without cyclosporine had a reduced number of de novo skin malignancies (44), and some patients experienced regression of skin cancers such as Kaposi’s sarcoma (KS) and SCC that were present prior to initiation of mTOR therapy (45–49). Here, MTOR is linked to skin cancer.